Vincent Boland: US regulator’s shot across bows of Amgen/Horizon deal leaves big pharma reeling
In an unusual move, the Federal Trade Commission is trying to block the acquisition of Dublin-based Horizon Therapeutics by US multi national Amgen, claiming it would enable the two companies to entrench a monopoly